Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Nervive
AddedFeb 17, 2024
UpdatedJun 18, 2026
Nervive

Nervive

Seed

Nervive, a Delaware C-corp, develops non-invasive treatments for brain ischemia with its VitalFlow Stimulator.

HQ
Akron, OH, US
Founded
2013
Overview
Compare
Fundraising
Employees

Nervive, founded in 2013 and headquartered in Akron, Ohio, is a Delaware C-corp focused on developing non-invasive treatments for brain ischemia. Its primary product, the VitalFlow Stimulator, addresses conditions such as cerebral artery vasospasm, ischemic stroke, and traumatic brain injury.

Nervive's innovative approach has positioned it as a key player in the medical technology market. The company's non-invasive platform technology offers significant potential for improving patient outcomes in brain ischemia treatment.

Nervive - Similar Companies

NeuroSave logo

NeuroSave

NirvaMed logo

NirvaMed

Cervel Neurotech logo

Cervel Neurotech

cervel.com

Progressive Nuero logo

Progressive Nuero

NeuroVasx logo

NeuroVasx

Epic Neuro logo

Epic Neuro

Mivi Neuroscience logo

Mivi Neuroscience

mivineuro.com

Neurvana Medical logo

Neurvana Medical

Nevro logo

Nevro

NeuRx Medical logo

NeuRx Medical

neurxmed.com

NeurAxis logo

NeurAxis

neuraxis.com

Neurodyne logo

Neurodyne

Scion Neurostim logo

Scion Neurostim

scionneurostim.com

Celvive logo

Celvive

Renerva logo

Renerva

renerva.com

Nervive - Quick Facts

Who are Nervive's competitors?

Companies similar to Nervive include NeuroSave, NirvaMed, Cervel Neurotech and Progressive Nuero.

When was Nervive founded?

Nervive was founded in 2013.

Where is Nervive's headquarters located?

Nervive's headquarters is located in Akron, OH, US.

When was Nervive's last funding round?

Nervive's most recent funding round was for $3.1M (USD) in October 2017.

How much has Nervive raised to-date?

As of Oct 6, 2017, Nervive has raised a total of $3.6M (USD).

How many employees does Nervive have?

Nervive has 6 employees as of Feb 4, 2024.

Nervive - Classification

Industry
  • Hardware
Ownership
  • Private
Technology
  • Technology
Geographic Exposure
  • United States
Revenue
  • Recurring
Customer
  • Enterprise
  • Government
Main Product
  • Medical Devices
Tags
  • Healthtech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
SIC
  • 5000Wholesale Trade-durable Goods
  • 5040Professional And Commercial Equipment And Supplies
  • 5047Medical, Dental, And Hospital Equipment And Supplies
Show 7 more industry codes
NAICS
  • 330000Manufacturing
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 3900Miscellaneous Manufacturing Industries
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified